Sotera Health Co (SHC) Stock
Fundamentals
Source: third-party data provider, as of October 12, 2026
Compare with SHC
Recent news
Sotera Health Q2 Earnings Call Highlights
Sotera Health Q2 Earnings Call Highlights
SHC
Sotera Health (SHC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Sotera Health (SHC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
SHC
Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates
Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates
SHC
Sotera Health (SHC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Sotera Health (SHC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
SHCTechnical indicators
- RSI 14
- 43.51
- MACD 12/26/9
- -0.17
- EMA 9 of MACD
- -0.11
- MACD histogram
- -0.06
- SMA 50
- $18.68
- Price below SMA 50
- EMA 50
- $18.35
- Price below EMA 50
- SMA 200
- $17.02
- Price above SMA 200
- EMA 200
- $17.33
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.21 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Sotera Health Q2 Earnings Call Highlights
Sotera Health Q2 Earnings Call Highlights
SHCSotera Health (SHC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Sotera Health (SHC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
SHCSotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates
Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates
SHCSotera Health (SHC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Sotera Health (SHC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
SHC
Sotera Health Company (SHC) Surpasses Q1 Earnings and Revenue Estimates
Sotera Health Company (SHC) Surpasses Q1 Earnings and Revenue Estimates
SHC
All You Need to Know About Sotera Health (SHC) Rating Upgrade to Buy
All You Need to Know About Sotera Health (SHC) Rating Upgrade to Buy
SHC
Sotera Health (SHC) Soars 8.2%: Is Further Upside Left in the Stock?
Sotera Health (SHC) Soars 8.2%: Is Further Upside Left in the Stock?
SHC
A $175 Million Move Into Sotera Health Signals Potential Opportunity Amid 21% Stock Drop
A $175 Million Move Into Sotera Health Signals Potential Opportunity Amid 21% Stock Drop
SHC
Sotera Health Shares Down 24% This Year. Is the Stock a Buy as One Investor Reveals Adding $3 Million More?
Sotera Health Shares Down 24% This Year. Is the Stock a Buy as One Investor Reveals Adding $3 Million More?
SHC
Sotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals
Sotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals
SHCAbout Sotera Health Co
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe and other regions.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael B. Petras Jr. | Executive Chairman of the Board | 1969 |
| Mr. Jonathan M. Lyons | Senior VP & CFO | 1978 |
| Mr. Michael P. Rutz | President of Sterigenics U.S., LLC | 1971 |
| Mr. Alton E. Shader | CEO & Director | 1973 |
| Mr. Robert G. Hauzie | Chief Information Officer | — |
| Ms. Erika Ostrowski | Senior VP, General Counsel & Corporate Secretary | — |
| Ms. Kristin A. Gibbs | Chief Marketing Officer | — |
| Mr. William O. Lehmann Jr., J.D., M.B.A. | Senior Vice President of Strategy & Corporate Development | 1966 |
| Ms. Sally R. Turner | Chief Human Resources Officer | — |
| Ms. Danielle J. Menture | Senior Vice President of Global Environmental, Health & Safety and Sustainability | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 12, 2026
Technical indicators
- RSI 14
- 43.51
- MACD 12/26/9
- -0.17
- EMA 9 of MACD
- -0.11
- MACD histogram
- -0.06
- SMA 50
- $18.68
- Price below SMA 50
- EMA 50
- $18.35
- Price below EMA 50
- SMA 200
- $17.02
- Price above SMA 200
- EMA 200
- $17.33
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $18.00
- Average
- $22.50
- High
- $25.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.2 | -16.1 | +13.6 | |||||||||
| 2022 | -7.6 | +1.9 | +1.4 | -6.9 | +3.6 | -7.4 | -2.3 | -11.4 | -60.1 | -6.6 | +20.9 | -5.2 |
| 2023 | +107.0 | -8.6 | +4.9 | -3.9 | -14.1 | +32.8 | +3.9 | -14.3 | -6.4 | -13.8 | +6.1 | +20.4 |
| 2024 | -12.1 | -2.0 | -17.5 | -4.3 | -0.8 | +3.6 | +19.8 | +13.3 | +8.7 | -3.7 | -17.0 | +3.2 |
| 2025 | +0.7 | -9.0 | -0.2 | +3.3 | +1.2 | -8.8 | +0.3 | +46.8 | -2.7 | +2.5 | +5.2 | +1.7 |
| 2026 | +2.4 | -11.2 | -9.9 | +4.6 | +0.9 | +14.2 | +0.6 | +5.1 | -1.0 | -0.3 |
